Dose-Escalation Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

Conditions: SARS CoV 2 Infection Interventions: Biological: IMNN-101 Sponsors: Imunon Not yet recruiting

Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials